Therapeutic effects of the direct renin inhibitor, aliskiren, on non-alcoholic steatohepatitis in fatty liver Shionogiob/obmale mice-Reference-Cited by-同舟云学术

Therapeutic effects of the direct renin inhibitor, aliskiren, on non-alcoholic steatohepatitis in fatty liver Shionogiob/obmale mice

Published:2013-07-21 Issue:8 Volume:44 Page:888-896
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Kishina Manabu¹,Koda Masahiko¹,Kato Jun¹,Tokunaga Shiho¹,Matono Tomomitsu¹,Sugihara Takaaki¹,Ueki Masaru¹,Murawaki Yoshikazu¹

Affiliation:

1. Division of Medicine and Clinical Science; Department of Multidisciplinary Internal Medicine; Faculty of Medicine; Tottori University; Yonago Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hepr.12186/fullpdf

Reference26 articles.

1. An overview of nonalcoholic steatohepatitis: past, present and future directions;Pascale;J Gastrointestin Liver Dis,2010

2. Prevalence, gender, ethnic variations, and prognosis of NASH;Hashimoto;J Gastroenterol,2011

3. Non-alcoholic fatty liver disease and the metabolic syndrome: an update;Rector;World J Gastroenterol,2008

4. The rennin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress;Marique;Med Clin North Am,2009

5. The renin angiotensin system and the metabolic syndrome;De Kloet;Physiol Behav,2010

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PPARα activation partially drives NAFLD development in liver-specific Hnf4a-null mice;The Journal of Biochemistry;2023-01-23

2. Insight into the hepatoprotective, hypolipidemic, and antidiabetic impacts of aliskiren in streptozotocin-induced diabetic liver disease in mice;Diabetology & Metabolic Syndrome;2022-10-31

3. Diabetic fibrosis;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2021-04

4. Aliskiren – A promising antioxidant agent beyond hypertension reduction;Chemico-Biological Interactions;2020-08

5. The use of aliskiren as an antifibrotic drug in experimental models: A systematic review;Drug Development Research;2019-10-12